Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial

[1]  Li Song,et al.  Association between the Changes in Trimethylamine N-Oxide-Related Metabolites and Prognosis of Patients with Acute Myocardial Infarction: A Prospective Study , 2022, Journal of cardiovascular development and disease.

[2]  Yu Xu,et al.  SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study , 2022, Diabetes care.

[3]  Gaosi Xu,et al.  Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. , 2022, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[4]  R. Holman,et al.  Empagliflozin in acute myocardial infarction: the EMMY trial , 2022, European heart journal.

[5]  Qian Zhang,et al.  Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites , 2022, Frontiers in Endocrinology.

[6]  Li Song,et al.  Association between trimethylamine N‐oxide and prognosis of patients with acute myocardial infarction and heart failure , 2022, ESC heart failure.

[7]  F. Gao,et al.  Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology , 2022, Frontiers in Cardiovascular Medicine.

[8]  M. Connelly,et al.  Temporal Course of Plasma Trimethylamine N-Oxide (TMAO) Levels in ST-Elevation Myocardial Infarction , 2021, Journal of clinical medicine.

[9]  H. Thiele,et al.  Association of plasma trimethylamine N-oxide levels with atherosclerotic cardiovascular disease and factors of the metabolic syndrome. , 2021, Atherosclerosis.

[10]  H. Heerspink,et al.  Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation. , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[11]  H. Sourij,et al.  Can sodium glucose cotransporter 2 (SGLT-2) inhibitors be beneficial in patients with acute myocardial infarction? , 2021, Kardiologia polska.

[12]  G. Tse,et al.  Trimethylamine N-oxide is associated with coronary atherosclerotic burden in non-ST-segment myocardial infarction patients: SZ-NSTEMI prospective cohort study. , 2021, Reviews in cardiovascular medicine.

[13]  J. Kałużna-Czaplińska,et al.  Trimethylamine N-oxide (TMAO) in human health , 2021, EXCLI journal.

[14]  B. Obermayer-Pietsch,et al.  Assessment of trimethylamine N-oxide (TMAO) as a potential biomarker of severe stress in patients vulnerable to posttraumatic stress disorder (PTSD) after acute myocardial infarction , 2021, European journal of psychotraumatology.

[15]  Hongbing Yan,et al.  Trimethylamine N-Oxide Was Not Associated With 30-Day Left Ventricular Systolic Dysfunction in Patients With a First Anterior ST-Segment Elevation Myocardial Infarction After Primary Revascularization: A Sub-analysis From an Optical Coherence Tomography Registry , 2020, Frontiers in Cardiovascular Medicine.

[16]  Z. dong,et al.  Trimethylamine N-Oxide is Associated with Heart Failure Risk in Patients with Preserved Ejection Fraction. , 2020, Laboratory medicine.

[17]  A. Meinitzer,et al.  Determination of Trimethylamine-N-oxide by a Simple Isocratic High-Throughput Liquid-Chromatography Tandem Mass-Spectrometry Method. , 2020, Clinical Laboratory.

[18]  Fei Guo,et al.  Plasma trimethylamine n-oxide is associated with renal function in patients with heart failure with preserved ejection fraction , 2020, BMC Cardiovascular Disorders.

[19]  J. Okun,et al.  Trimethylamine‐N‐oxide is elevated in the acute phase after ischaemic stroke and decreases within the first days , 2020, European journal of neurology.

[20]  A. Franks,et al.  Plasma Levels of TMAO can be Increased with 'Healthy' and 'Unhealthy' Diets and Do Not Correlate with the Extent of Atherosclerosis but with Plaque Instability. , 2020, Cardiovascular research.

[21]  W. Lieb,et al.  Trimethylamine-N-oxide (TMAO) determined by LC-MS/MS: distribution and correlates in the population-based PopGen cohort , 2020, Clinical chemistry and laboratory medicine.

[22]  J. Manson,et al.  Long-Term Changes in Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk. , 2020, Journal of the American College of Cardiology.

[23]  L. Cai,et al.  The gut microbiota and its interactions with cardiovascular disease , 2020, Microbial biotechnology.

[24]  Zongliang Yu,et al.  Trimethylamine N‐oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction , 2020, ESC heart failure.

[25]  A. Oulhaj,et al.  Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial. , 2019, American heart journal.

[26]  F. Wang,et al.  Gut Microbial Metabolite Trimethylamine N-Oxide Is Related to Thrombus Formation in Atrial Fibrillation Patients. , 2019, The American journal of the medical sciences.

[27]  T. Ishigami,et al.  Microbiota-derived Trimethylamine N-oxide Predicts Cardiovascular Risk After STEMI , 2019, Scientific Reports.

[28]  Li Song,et al.  Relation of Circulating Trimethylamine N-Oxide With Coronary Atherosclerotic Burden in Patients With ST-segment Elevation Myocardial Infarction. , 2019, The American journal of cardiology.

[29]  Li Song,et al.  Plasma Trimethylamine N-Oxide as a Novel Biomarker for Plaque Rupture in Patients With ST-Segment–Elevation Myocardial Infarction , 2019, Circulation. Cardiovascular interventions.

[30]  L. Pączek,et al.  Chronic, low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats. , 2018, American journal of physiology. Heart and circulatory physiology.

[31]  Donald J L Jones,et al.  Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure: results from BIOSTAT‐CHF , 2018, European journal of heart failure.

[32]  J. Kaski,et al.  The Role of Microbiota in Cardiovascular Risk: Focus on Trimethylamine Oxide. , 2018, Current problems in cardiology.

[33]  T. Weir,et al.  SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice , 2018, Cardiovascular Diabetology.

[34]  A. Sannino,et al.  Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis , 2017, European heart journal.

[35]  J. Manson,et al.  Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta‐Analysis of Prospective Studies , 2017, Journal of the American Heart Association.

[36]  L. Räber,et al.  Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors , 2017, European heart journal.

[37]  S. Hazen,et al.  Intestinal Microbiota‐Generated Metabolite Trimethylamine‐N‐Oxide and 5‐Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE‐Like Patient Cohort , 2016, Journal of the American Heart Association.

[38]  P. Stenvinkel,et al.  Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease , 2016, PloS one.

[39]  S. Bhushan,et al.  Choline Diet and Its Gut Microbe–Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload–Induced Heart Failure , 2016, Circulation. Heart failure.

[40]  Zeneng Wang,et al.  Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. , 2015, Journal of cardiac failure.

[41]  S. Hazen,et al.  Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. , 2014, Analytical biochemistry.

[42]  D. Raj,et al.  The gut microbiome, kidney disease, and targeted interventions. , 2014, Journal of the American Society of Nephrology : JASN.

[43]  OUP accepted manuscript , 2022, The American Journal of Clinical Nutrition.